Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
April 1, 2019 Off

Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application

By BusinessWire

OSAKA, Japan & AMSTERDAM, NL–(BUSINESS WIRE)–Shionogi & Co., Ltd (hereafter “Shionogi”) announces that the Marketing Authorisation Application (MAA) submission for…

April 1, 2019 Off

EMA Accepts Takeda’s MAA for Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease

By BusinessWire

Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only…

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
March 31, 2019 Off

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

By BusinessWire

Data Presented at 2019 AACR Annual Meeting Supports Novel Conditionally Active Biologics CAR-T Technology ATLANTA–(BUSINESS WIRE)–F1 Oncology, Inc., a biotechnology…

FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations
March 29, 2019 Off

FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations

By BusinessWire

Label Updated to Include Reduction in Exacerbations and Major Adverse Cardiovascular Event Safety Data in Cardiovascular-Risk COPD Patients MORRISVILLE, N.C.–(BUSINESS…

Can-Fite Files Annual Report for the Year Ended December 31, 2018
March 29, 2019 Off

Can-Fite Files Annual Report for the Year Ended December 31, 2018

By BusinessWire

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule…

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
March 29, 2019 Off

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019

By BusinessWire

First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia…

March 29, 2019 Off

Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR

By BusinessWire

TORONTO–(BUSINESS WIRE)–Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from…

March 29, 2019 Off

Arch Oncology to Present Preclinical Data on Highly-Differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019

By BusinessWire

BRISBANE, Calif. & ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class…

March 29, 2019 Off

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

By BusinessWire

Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the…

March 29, 2019 Off

Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation

By BusinessWire

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd.…

Posts pagination

Previous 1 … 3,318 3,319 3,320 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine